In 2017, Joël de Beer dropped out of his Ph.D. program and began trying to build a leading genetic medicines company from a site the size of a parking space. After working quietly for several years to realize the vision, de Beer’s Anjarium Biosciences has now broken cover with 55.5 million Swiss francs ($61 million) from top-tier investors including Abingworth, Gimv and Pfizer Ventures.
The lymph nodes are an important gateway in the formation of metastatic cancer, as they take in cancer cells and then spew them out into the body, where they can form new tumors in distant tissues. Now, scientists led by the Dartmouth-Hitchcock Medical Center have discovered T cells in the lymph nodes that have the power to kill melanoma cells before they can spread—a potential new target for therapeutic development.
The Brisa app will collect daily health data like activity, sleep and dietary habits and give users a place to track their day-to-day MS symptoms. After analyzing that information, the “digital companion” will be able to pinpoint potential areas of improvement and suggest lifestyle changes that might help users better manage the condition in tandem with their existing treatment plans.
Theravance Biopharma’s rotten run has triggered big changes at the biotech. With a phase 3 rare disease study becoming the third trial to fail in as many months, Theravance is axing 75% of its staff and narrowing its focus to respiratory diseases.
Sanofi’s Principia Biopharma is taking a one-two punch. Just days after one of the subsidiary’s key BTK inhibitors crashed out of clinical testing, Sanofi has now disclosed it will wind down Principia’s San Francisco laboratories and lay off roughly three dozen employees in the process.
Medtronic is launching a pilot program to screen real-world data for people who may have a heightened risk of sudden cardiac arrest, with the goal of pairing them up with potentially life-saving hardware before a heart attack occurs.
Masimo finds pot of gold with CE mark for Rainbow SuperSensor, to monitor 12 blood parameters at once
Normally, chasing rainbows is an inherently futile act. Masimo’s pursuit, however, is the rare one proven fruitful, with a new CE mark for its Rainbow SuperSensor.
Before amyloid beta peptides can form the brain plaques that have been implicated in Alzheimer’s and other brain disorders, they have to bind to “fibrils,” protein aggregates that grow over time. But sometimes misaligned chemical forces prevent the peptides from locking onto fibrils—a failure that researchers now say could inspire new treatments.
Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia.
About four months after the abrupt exit of CEO Mike Coyle, a new leader is taking the helm at cardiac monitor maker iRhythm Technologies. Quentin Blackford will step into the dual role of CEO and president of the San Francisco-based company, effective Oct. 4. At that time, he’ll also join iRhythm’s board of directors.